Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects .

Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to enhance patient compliance.

Objective: This study was performed to compare the single-dose pharmacokinetic properties and tolerability of DP-R208 (candesartan and rosuvastatin FDC) to those of each component administered alone in healthy Korean male volunteers.

Materials And Methods: A total of 40 healthy Korean volunteers were enrolled in this randomized, open-label, single-dose, two-treatment, two-way crossover study.

Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk.

Purpose: The aim of this study was to evaluate the efficacy and tolerability of rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk.

Methods: This was a 12-week, randomized, double-blind, placebo-controlled, multicenter study. A total of 337 patients were screened.

Anti-inflammatory and immune-modulating effect of Ulmus davidiana var. japonica Nakai extract on a macrophage cell line and immune cells in the mouse small intestine.

Ethnopharmacological Relevance: Traditional Oriental medicine has utilized the barks of the stem and root of Ulmus davidiana var. japonica Nakai (UD) to treat inflammatory disorders.

Aim Of The Study: The purpose of the present study was to evaluate UD's anti-inflammatory and immune-modulating effects on a lipopolysaccharide (LPS)-stimulated macrophage cell line and small-intestinal lamina propria (LP) cells, respectively.